AR013190A1 - Semaforina l humana (h-sema-l) que contiene un dominio de sema caracteristico, un acido nucleico que la codifica, procedimiento para lapreparacion de semaforinas, utilizacion de la semaforina tipo l y utilizacion de la secuencia de acido nucleico para la fabricacion de un medicamento, - Google Patents

Semaforina l humana (h-sema-l) que contiene un dominio de sema caracteristico, un acido nucleico que la codifica, procedimiento para lapreparacion de semaforinas, utilizacion de la semaforina tipo l y utilizacion de la secuencia de acido nucleico para la fabricacion de un medicamento,

Info

Publication number
AR013190A1
AR013190A1 ARP980103298A ARP980103298A AR013190A1 AR 013190 A1 AR013190 A1 AR 013190A1 AR P980103298 A ARP980103298 A AR P980103298A AR P980103298 A ARP980103298 A AR P980103298A AR 013190 A1 AR013190 A1 AR 013190A1
Authority
AR
Argentina
Prior art keywords
semaphorin
sema
nucleic acid
nucleic
procedure
Prior art date
Application number
ARP980103298A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1997129211 external-priority patent/DE19729211C2/de
Priority claimed from DE1998105371 external-priority patent/DE19805371A1/de
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR013190A1 publication Critical patent/AR013190A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Semaforina L humana que contiene un dominio de Sema característico,donde la proteína tiene un péptido de senal terminal en N y en la zona terminal en C undominio transmembranal, siendo designada la semaforina como semaforina del tipo L(Sema L), yder ivados de la semaforina del tipo L. La proteína está descriptaasí como también varios constructos de ácidos nucleicos que contienen el gen para la correspondiente secuencia de proteína semaforina del tipo L, ARNm y lasecunecia de gencompleta. Un procedimiento para preparar una semaforina del tipo L y derivados relacionados y la utilizacion de la proteína y secunecias deácidos nucleicos derivados para la fabricacion de un medicamento. Además se implementa un método paraidentificar age ntes inmunomoduladores que comprendenincubar una semaforina L bajo condiciones definidas con un agente a ser ensayado. También se refiere a un anticuerpo de la semaforina y la preparaciondel mismo.
ARP980103298A 1997-07-09 1998-07-07 Semaforina l humana (h-sema-l) que contiene un dominio de sema caracteristico, un acido nucleico que la codifica, procedimiento para lapreparacion de semaforinas, utilizacion de la semaforina tipo l y utilizacion de la secuencia de acido nucleico para la fabricacion de un medicamento, AR013190A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1997129211 DE19729211C2 (de) 1997-07-09 1997-07-09 Humanes Semaphorin L (H-Sema-L) und korrespondierende Semaphorine in anderen Spezies
DE1998105371 DE19805371A1 (de) 1998-02-11 1998-02-11 Humanes Semaphorin L (H-Sema-L) und korrespondierende Semaphorine in anderen Spezies

Publications (1)

Publication Number Publication Date
AR013190A1 true AR013190A1 (es) 2000-12-13

Family

ID=26038116

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103298A AR013190A1 (es) 1997-07-09 1998-07-07 Semaforina l humana (h-sema-l) que contiene un dominio de sema caracteristico, un acido nucleico que la codifica, procedimiento para lapreparacion de semaforinas, utilizacion de la semaforina tipo l y utilizacion de la secuencia de acido nucleico para la fabricacion de un medicamento,

Country Status (15)

Country Link
US (2) US20020037851A1 (es)
EP (1) EP0892047A3 (es)
JP (1) JPH11235189A (es)
KR (1) KR19990013797A (es)
CN (1) CN1209436A (es)
AR (1) AR013190A1 (es)
AU (1) AU744447B2 (es)
BR (1) BR9802360A (es)
CA (1) CA2237158A1 (es)
CZ (1) CZ214998A3 (es)
HU (1) HUP9801511A3 (es)
ID (1) ID20819A (es)
PL (1) PL327385A1 (es)
RU (1) RU2218181C2 (es)
TR (1) TR199801301A3 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
EP1066317A2 (en) * 1998-01-30 2001-01-10 Smithkline Beecham Plc Novel compounds
WO1999045114A2 (en) * 1998-03-03 1999-09-10 Zymogenetics, Inc. Human semaphorin zsmf-7
ES2315011T3 (es) * 1998-05-14 2009-03-16 Immunex Corporation Polipeptidos de semaforina.
AU772630B2 (en) * 1999-01-14 2004-05-06 Novartis Ag Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
CN100398551C (zh) * 2001-11-09 2008-07-02 乔治敦大学 新的血管内皮细胞生长抑制剂同种型
JP2005173484A (ja) * 2003-12-15 2005-06-30 Canon Inc 画像形成装置及びプロセスカートリッジ
FR2932388B1 (fr) * 2008-06-17 2013-03-29 Univ Rabelais Francois Nouvelles proteines de fusion et leur application pour la preparation de vaccins contre l'hepatite c
MX353352B (es) 2009-05-08 2018-01-10 Vaccinex Inc Anticuerpos anti-cd100 y metodos para su uso.
EP2766093B1 (en) 2011-10-11 2018-02-21 Vaccinex, Inc. Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
US9090709B2 (en) 2012-03-28 2015-07-28 Vaccinex, Inc. Anti-SEMA4D antibodies and epitopes
US10494440B2 (en) 2012-05-11 2019-12-03 Vaccinex, Inc. Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
US9828435B2 (en) 2013-06-25 2017-11-28 Vaccinex, Inc. Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency
NZ630881A (en) 2013-10-10 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treatment of atherosclerosis
NZ630892A (en) 2013-10-21 2016-03-31 Vaccinex Inc Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
CN104034761B (zh) * 2014-05-14 2017-01-04 浙江大学 一种检测气味结合蛋白与信息素结合过程的装置及方法
AU2018225493A1 (en) * 2017-02-22 2019-08-01 Vaccinex, Inc. Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639856A (en) 1993-09-13 1997-06-17 The Regents Of The University Of California Semaphorin gene family
US5416197A (en) * 1993-10-15 1995-05-16 Trustees Of The University Of Pennsylvania Antibodies which bind human collapsin
EP1066317A2 (en) * 1998-01-30 2001-01-10 Smithkline Beecham Plc Novel compounds
WO1999045114A2 (en) * 1998-03-03 1999-09-10 Zymogenetics, Inc. Human semaphorin zsmf-7
US6225285B1 (en) * 1998-03-11 2001-05-01 Exelixis Pharmaceuticals, Inc. Semaphorin K1
ES2315011T3 (es) * 1998-05-14 2009-03-16 Immunex Corporation Polipeptidos de semaforina.
EP1803730A1 (en) * 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins

Also Published As

Publication number Publication date
US20060029998A1 (en) 2006-02-09
TR199801301A2 (xx) 1999-01-18
AU744447B2 (en) 2002-02-21
CN1209436A (zh) 1999-03-03
TR199801301A3 (tr) 1999-01-18
JPH11235189A (ja) 1999-08-31
PL327385A1 (en) 1999-01-18
AU7507698A (en) 1999-01-21
ID20819A (id) 1999-03-11
BR9802360A (pt) 1999-10-05
US20020037851A1 (en) 2002-03-28
EP0892047A2 (de) 1999-01-20
HUP9801511A2 (hu) 1999-05-28
CZ214998A3 (cs) 1999-01-13
EP0892047A3 (de) 2000-03-08
HU9801511D0 (en) 1998-09-28
RU2218181C2 (ru) 2003-12-10
US7339030B2 (en) 2008-03-04
KR19990013797A (ko) 1999-02-25
CA2237158A1 (en) 1999-01-09
HUP9801511A3 (en) 2001-08-28

Similar Documents

Publication Publication Date Title
AR013190A1 (es) Semaforina l humana (h-sema-l) que contiene un dominio de sema caracteristico, un acido nucleico que la codifica, procedimiento para lapreparacion de semaforinas, utilizacion de la semaforina tipo l y utilizacion de la secuencia de acido nucleico para la fabricacion de un medicamento,
CN108913691B (zh) 表皮干细胞中采用CRISPR-Cas***进行Card3基因敲除
ES2059361T3 (es) Complejo de proteinas recombinantes que tiene actividad de factor viii:c su produccion y uso.
ATE386800T1 (de) Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
CY1108538T1 (el) Χιμαιρικα πεπτιδια β-αμυλοειδους
TR199801794T2 (xx) �nsan bikunini.
ES2004133A6 (es) Procedimiento para la preparacion de una nueva proteina.
KR20120054644A (ko) 이량체화 펩티드
DE60043428D1 (de) POLYPEPTIDE MIT VERZWEIGUNGSENZYM-AKTIVITäT UND FüR DIESE KODIERENDE NUKLEINSäUREN
AR123158A1 (es) Proteínas de fusión del ligando para flt3 y métodos de uso
ES2124470T3 (es) Lectina recombinante de muerdago.
DE69535206D1 (de) Das einbringen von nukleinsäuremolekülen in schleimhautgewebe
HUP0002472A2 (hu) Izolált dendritikus sejtmembrán-fehérje gének
Tostivint et al. Revisiting the evolution of the somatostatin family: Already five genes in the gnathostome ancestor
SE8204811L (sv) Dna-fragment innefattande en signalsekvens
Willis Partial amino acid sequences of cuticular proteins from Hyalophora cecropia
WO2001087978A3 (en) Human abc transporter and its use
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
WO2002050111A3 (en) Isolated laminin 10
Otvos Jr et al. Glycosylation of synthetic T helper cell epitopic peptides influences their antigenic potency and conformation in a sugar location-specific manner
DK1287142T3 (da) Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvens
CN105504070B (zh) 一种四分支多肽及其应用
WO1992011370A3 (de) Von proteinen des hepatitis c-virus abgeleitete polypeptide und deren verwendung
Francis et al. Carboxyl-terminal amino acid sequences of two variant forms of the gamma chain of human plasma fibrinogen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure